Skip to content

Bio-Rad Laboratories, Inc. BIO.B Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Abbott logo
AbbottABT
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Illumina logo
IlluminaILMN

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Bio-Rad Laboratories, Inc. (BIO.B) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $1.06B in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
Bio-Rad Laboratories, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) decreased by 7.2% year-over-year, from $1.14B to $1.06B.
What is the long-term trend for Bio-Rad Laboratories, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Over 5 years (2020 to 2025), Bio-Rad Laboratories, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a 25.2% compound annual growth rate (CAGR), from $328.91M to $1.01B.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.